Condition: Refractory Systemic Lupus Erythematosus · Refractory Lupus Nephritis · Sponsor: Guangdong Provincial People's Hospital
This is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK010 or NK042 in combination with rituximab (RTX) for the treatment of patients with refractory systemic lupus erythematosus (SLE) or lupus nephritis (LN) in China.
This description comes directly from the study's public registry record.
Xueqing Yu, Ph.D · 8620-83827897 · yuxueqing@gdph.org.cn
Li Fan · 8615913106705 · fanli@gdph.org.cn
Always discuss trial participation with your own doctor first.
| Guangdong Provincial People's Hospital | Guangzhou, Guangdomg, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06676631